Around the World with LES


Around the World with LES

Intellectual property, licensing and business development professionals will gather around the world to celebrate World IP Day and the importance of IP to the global economy.  Participating LES (USA & Canada) Chapters and LESI societies will host events celebrating World IP Day on April 26, 2012.

New York City Chapter Meeting

April 26, 2012
5:30 PM to 8 PM

Pryor Cashman, LLP
7 Times square (Broadway, between 41st and 42nd Street)
New York, NY 10036

Medical Devices – New Rules, New Opportunities

The Medical Device industry continues to expand both in the US and internationally.  Product development is being driven by smaller companies and start ups, and the US remains a primary source of new products. Several factors have changed this landscape recently and this has impacted how ‘Strategics’, the Venture Capital, Private Equity and angel communities now view investment opportunities.

A distinguished panel of experts will explore the macro trends and current conditions in the medical device industry from the perspective of start-ups and large, well-established manufacturers. The discussion also will focus on deal structures / business development activities, differing regulatory paths of international vs. US approvals of devices, as well as new IP considerations resulting from recent legal developments.

Christine T. Fischette, Ph.D., Senior Advisor, Griffin Securities and President & CEO of CTF, LLC, Consulting

Richard Russo
, CEO, Endomedix
Paul Higham, Ph.D., President, Higham Consulting, Formerly Director, Orthopaedics, Stryker
John Hanish, Ph.D.,  Partner, Patent Litigation, Goodwin & Procter, LLP


Early by April 24, 2012
LES Member: $30
Non-Member: $40
LES Student Member: No charge

LES Member: $50
Non-Member: $60
LES Student Member: No charge

Online Registration Deadline: Tuesday, April 24, 12 PM EST
Onsite Registration Available 

No refunds after April 24
Substitutions are permitted


Christine T. Fischette, Ph.D.
Christine T. Fischette, Ph.D. is Senior Advisor at Griffin Securities, Inc., New York, NY and President and CEO of her own Corporate Strategy / Business Development Consulting firm. She is Chair of the M&A Committee for the Licensing Executive Society (LES) and Co-Chair for the LES New York Chapter.

Formerly she was President of Enzo Therapeutics, Inc., a division of Enzo Biochem (ENZ:NYSE), and spent 25+ years in Big Pharma covering multiple areas of drug development, commercialization and business development.

Dr. Fischette functioned as Executive Director and Head of Negotiation, Global Business Development and Licensing at Novartis Pharmaceuticals. And, at Pfizer, she directed preclinical/clinical development, medical marketing, marketing and business development.

Prior to Pfizer, she conducted research as Senior Scientist at Hoffmann-La Roche, Inc. and as a Post-Doctoral Fellow/Research Associate at Rockefeller University, NY.

Dr. Fischette holds a Ph.D. in Physiology from the University of Medicine & Dentistry of New Jersey. She has authored over 50 publications in peer-reviewed publications, including Science.

 Richard Russo
Richard Russo has had a wide-ranging career in the medical device industry.  He has held positions in sales management, product management and marketing.  He also managed regulatory affairs, clinical trials, product development, strategic planning and acquisitions.

Richard has worked for such organizations as American Hospital Supply Corporation, CR Bard, Electro-Biology and Osteotech. He was start up manager in Meditron Corporation, a firm which was successfully acquired by a public company.

Richard is currently the president & CEO of a start up medical device venture, Endomedix, Inc. Endomedix has developed a patented platform technology that will produce devices for surgical hemostasis, tissue sealants and tissue engineering.  He is currently in the midst of a seed round financing. Prior to Endomedix, Richard was President-International of Osteotech and launched and ran a successful outside the US business from locations in France and Bulgaria.

John P. Hanish, Ph.D.
Patent Litigation and Licensing

John P. Hanish, Ph.D., is a partner in Goodwin Procter’s Patent Litigation Practice.  He has 13 years of trial and appellate experience in patent, trade secret and licensing disputes related to pharmaceuticals, biotechnology, medical devices, electronics and consumer products.

Recently, he represented a firm in an arbitration conducted in the International Centre For Dispute Resolution in which the client sought indemnification for breach of provisions in a patent license and development agreement that related to therapeutic compositions combining monoclonal antibodies and antineoplastic agents for the treatment of cancer.

Mr. Hanish’s other engagements related to patent license agreements or medical devices have involved kits for the detection of methicillin-resistant Staph aureus (MRSA), immunoassay diagnostic tests, including over-the-counter pregnancy tests and ovulation predicting devices, knee braces, and cleaning and disinfecting solutions for soft contact lenses.

He is the co-author of “(Im) pure Questions About Claim Construction in Patent Cases After Phillips,” and “Patent Business and Litigation Issues for Universities”.

Scientific Experience
Mr. Hanish was a Winston Post-doctoral fellow at the Rockefeller University and a Research Scientist at the Sloan-Kettering Institute.  He authored nine scientific publications in peer-reviewed journals including Science and the Proceedings of the National Academy of Sciences.

J.D., New York University School of Law, 1998 (Albert Podell Oral Advocacy Award)
Ph.D., Biochemistry and Molecular Biology, University of Chicago, 1990
B.S., Chemistry and History, North Dakota State University, 1986

Paul Higham
Paul Higham is an experienced Global Business Development and Technical Executive with extensive experience in the Medical Device Industry; working at Stryker and Pfizer Hospital Products Group before establishing Higham Consulting.

Paul has experience  in business development activities such as negotiation of term sheets, contracts and due diligence activities, and technology development from bench top to commercialization, portfolio analysis, identification of new technologies for revenue expansion.
He has developed  over $1 billion in global sales..
Paul has: 28 issued USA patents and equivalent international patents;32 peer reviewed publications,and, has presented at over 50 international conferences


Online Registration Closed
Onsite Registration Available



Online Registration

Program & Location
Arnold Burstein
BioClara Group

Christine Fischette
Senior Advisor
Griffin Securities


Interested in volunteering your time at your local chapter's ATW event? Email us at for more information.


Several LESI Societies, including Austria, Korea, Italy, Mexico, Spain-Portugal and France will be hosting Around the World events. For more information, please visit the LESI website.